Proliferation characteristics in pediatric Hodgkin's lymphoma point to a cell cycle arrest in the G1 phase

Modern Pathology

Volumn 18, Issue 11, 2005, Pages 1440-1447

  Tiemann, Markus ^a   Claviez, Alexander ^a   Lüders, Heike ^b   Zimmermann, Martin ^c   Schellong, Günther ^d   Dörffel, Wolfgang ^b   Parwaresch, Reza ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b HELIOS KLINIKUM BERLIN BUCH   (Germany)

^c LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Cell cycle; Children; Hodgkin's lymphoma; Outcome; Proliferation rate

Indexed keywords

KI 67 ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE LOCATION; HISTIOCYTE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STANDARDIZATION; TUMOR CELL;

ADOLESCENT; ADULT; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; G1 PHASE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; NUCLEAR PROTEINS; PROGNOSIS; REED-STERNBERG CELLS; SURVIVAL ANALYSIS;

EID: 27144454309     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800466     Document Type: Article

References (42)

1. Hall PA, Richards MA, Gregory WM, et al. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol 1988;154:223-235.
2. Stokke T, Smeland EB, Kvaloy S, et al. Tumour cell proliferation, but not apoptosis, predicts survival in B-cell non-Hodgkin's lymphomas. Br J Cancer 1998;77:1839-1841.
3. Gerdes J, Stein H, Pileri S, et al. Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet 1987;2:448-449.
4. Grogan TM, Lippman SM, Spier CM, et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 1988;71:1157-1160.
5. Mochen C, Giardini R, Costa A, et al. MIB-1 and S-phase cell fraction predict survival in non-Hodgkin's lymphomas. Cell Prolif 1997;30:37-47.
6. Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20.
7. Gerdes J, Dallenbach F, Lennert K, et al. Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol 1984;2:365-371.
8. Duchrow M, Schlüter C, Wohlenberg C, et al. Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67. Cell Prolif 1996;29:1-12.
9. Schmidt MH, Broll R, Bruch HP, et al. The proliferation marker pKi-67 organizes the nucleolus during the cell cycle depending on Ran and cyclin. Br J Pathol 2003;199:18-27.
10. Kreipe H, Wacker HH, Heidebrecht HJ, et al. Determination of the growth fraction in non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen. Am J Pathol 1993;142:1689-1694.
11. Cattoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-363.
12. Gerdes J, van Baarlen J, Pileri S, et al. Tumor cell growth fraction in Hodgkin's disease. Am J Pathol 1987;128:390-393.
13. Claviez A, Tiemann M, Peters J, et al. The impact of EBV, proliferation rate, and Bcl-2 expression in Hodgkin's disease in childhood. Ann Hematol 1994;68:61-66.
14. Abele MC, Valente G, Kerim S, et al. Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease. An immunohistochemical study with Ki67 and MIB-1 monoclonal antibodies. Haematologica 1997;82:281-285.
15. Morente MM, Piris MA, Abraira V, et al. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood 1997;90:2429-2436.
16. Aisenberg AC. Malignant Lymphoma. Biology, Natural History, and Treatment. Lea Febiger: Malvern, PA, 1991.
17. Hall PA, Levison DA. Assessment of cell proliferation in histological material. J Clin Pathol 1990;43:184-192.
18. Garcia JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003;101:681-689.
19. Bai M, Tsanou E, Agnantis NJ, et al. Proliferation profile of classical Hodgkin's lymphomas. Increased expression of the protein cyclin D2 in Hodgkin's and Reed-Sternberg cells. Mod Pathol 2004;17:1338-1345.
20. Heidebrecht HJ, Buck F, Steinmann J, et al. p100: a novel proliferation-associated nuclear protein specifically restricted to cell cycle phases S, G2, and M. Blood 1997;90:226-233.
21. Heidebrecht HJ, Adam-Klages S, Szczepanowski M, et al. repp86: A human protein associated in the progression of mitosis. Mol Cancer Res 2003;1:271-279.
22. Schellong G, Pötter R, Brämswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999;17:3736-3744.
23. Dörffel W, Lüders H, Rühl U, et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Pädiatr 2003;215:139-145.
24. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966;26:1063-1083.
25. Stein H, Delsol G, Pileri S, et al. Hodgkin lymphoma In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001, pp 237-253.
26. Bennett MH, MacLennan KA, Easterling MJ, et al. The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease: an analysis of 271 non-laparotomised cases (BNLI report no. 22). Clin Radiol 1983;34:497-501.
27. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-748.
28. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-580.
29. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219-229.
30. Ishii Y, Takami T, Yuasa H, et al. Two distinct antigen systems in human B lymphocytes: identification of cell surface and intracellular antigens using monoclonal antibodies. Clin Exp Immunol 1984;58:183-192.
31. Schwarting R, Gerdes J, Dürkop H, et al. BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol- resistant epitope. Blood 1989;74:1678-1689.
32. Rudolph P, Knuchel R, Endl E, et al. The immunohistochemical marker Ki-S2: cell cycle kinetics and tissue distribution of a novel proliferation-specific antigen. Mod Pathol 1998;11:450-456.
33. Kaplan ES, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
34. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
35. Morgan KG, Quirke P, O'Brien CJ, et al. Hodgkin's disease: a flow cytometric study. J Clin Pathol 1988;41:365-369.
36. Joensuu H, Klemi PJ, Korkeila E. Prognostic value of DNA ploidy and proliferative activity in Hodgkin's disease. Am J Clin Pathol 1988;90:670-673.
37. Erdkamp FL, Breed WP, Schouten HC, et al. DNA aneuploidy and cell proliferation in relation to histology and prognosis in patients with Hodgkin's disease. Ann Oncol 1993;4:75-80.
38. Drexler HG, Gignac SM, Hoffbrand AV, et al. Formation of multinucleated cells in a Hodgkin's-disease-derived cell line. Int J Cancer 1989;43:1083-1090.
39. Gupta RK, Lister TA, Bodmer JG. Proliferation of Reed-Sternberg cells and variants in Hodgkin's disease. Ann Oncol 1994;5(Suppl 1):117-119.
40. Schlegelberger B, Weber-Matthiesen K, Himmler A, et al. Cytogenetic findings and results of combined immunophenotyping and karyotyping in Hodgkin's disease. Leukemia 1994;8:72-80.
41. Falzetti D, Crescenzi B, Matteuci C, et al. Genomic instability and recurrent breakpoints are main cytogenetic findings in Hodgkin's disease. Haematologica 1999;84:298-305.
42. Gruss HJ, Kadin ME. Pathophysiology of Hodgkin's disease: functional and molecular aspects. Baillieres Clin Haematol 1996;9:417-446.